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Introduction
It has long been realised that linear dosing according to 
total body weight (TBW) results in oversdosing the obese 
and underdosing small children. As far back as 1969, in 
a study on induction doses of thiopentone, Wulfsohn and 
Joshi1 concluded that thiopentone was better administered 
according to lean body mass (LBM) than TBW. They 
reasoned that endomorphic somatotypes required less 
thiopentone than mesomophs and ectomorphs of the same 
TBW, because they had less LBM. They pointed out that 
there is a strong association between LBM, cardiac output 
and basal metabolic rate, and suggested that the LBM 
contained the “pharmacologically active mass”. Recently, 
several publications have emerged that suggest that dosing 
of other anaesthetic drugs to obese patients, such as 
remifentanil2  and propofol,3,4 should be based on LBM.
An obese person’s weight gain is not solely due to increased 
fat tissue. Figure 1 illustrates that should a person who is 
1.75-m tall and with an ideal body weight [approximately 
70 kg and a body mass index (BMI) of 23 kg/m2] become 
obese, this would mainly be due to a roughly parallel 
increase of fat. However, the weight gain is not only the result 
of an increase in fat tissue, but is also owing to nonlinear 
increases in the size of other organs, such as muscle, 
liver, gut, etc (Figure 1). As a result, there is a nonlinear 
association between TBW and drug disposition. Many 
nonlinear weight adjustors for dosage to obese patients 
have been suggested, e.g. body surface area. In 2004, after 
an extensive literature review, Green and Duffull concluded 
that LBW was the best dose adjustor for pharmacokinetic 
(PK) studies in the obese.5  
The most common method of calculating LBM is by the 
“James” equations.6 However, they cannot be applied to 
morbidly obese patients (BMI > 40 kg/m2) because of an 
anomalous feature of the James’ equations whereby after 
a BMI of roughly 40 kg/m2, LBM starts to decline with 
increasing TBW. This can even result in a negative value in 
the super-obese (Figure 2).
This anomaly presents a problem with the administration 
of two commonly used drugs in anaesthesia by target-
controlled infusion (TCI). In the case of propofol, the weight, 
gender and age-adjusted “Schnider” PK parameter set7 has 
been implemented in the commercially available TCI infusion 
pumps that are available today in most countries outside the 
USA. The equation for calculating total body clearance for 
morbidly obese patients results in exponentially increasing 
calculations for clearance, and therefore in gross overdosing 
when propofol is administered by infusion (Figure 3).
The opposite occurs with remifentanil using the “Minto” PK 
parameter set,8 namely calculations that result in decreasing 
clearance for the morbidly obese (Figure 4).
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Wulfsohn & Joshi. Br J Anaesth 1969; 41:516 
IBW: ideal body weight
Figure 1: Weight gain of a 1.75 m tall male due to obesity.  The 
weight gain results from increased fat mass as well as fat-free 
mass (e.g. muscle).
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As a result, TCI pump manufacturers will not permit users 
to enter TBW that results in BMIs that are greater than 
42 kg/m2 in men, and 35 kg/m2 in women. This is unfortunate 
for anaesthesiologists who manage morbidly obese and 
super-obese patients.  
A new method of calculating LBM has recently been 
introduced. Janmahasatian et al9 measured fat-free mass 
(FFM) using dual-energy X-ray absorptiometry in a study 
on 373 patients whose BMIs ranged from 17.1-69.9 kg/m2. 
(For clinical purposes, LBM and FFM can be regarded 
as being equivalent).9 The resulting “Janmahasatian” 
equations do not suffer from the “James” anomaly (Figure 5). 
Subsequent studies using the “Janmahasatian” equations 
suggest improved TCI of remifentanil2 (Figure 6) and propofol4 
to morbidly obese patients, as well as improved induction of 
anaesthesia using propofol.3 Whether or not implementing 
the “Janmahasatian” equations in the “Schnider” model for 
propofol will result in satisfactory TCI to morbidly obese 
patients remains to be demonstrated.
Allometric scaling has recently come to the fore as 
an alternate method of dose scaling in anaesthetic 
pharmacology. Allometry is the study of the relationship 
between size and shape. If an object increases in size while 
retaining its shape, i.e. grows isometrically, its surface area 
and volume (and therefore its weight) increase exponentially 
in proportion to its increased length, but at different rates. 
Examples of isometric change include a cube or a sphere. 
If the length of the side of a cube (or the radius of a sphere) 
is doubled, the surface area increases fourfold, but the 
volume (and therefore the weight) increases eightfold. 
Simply put, as length increases, weight increases more 
rapidly than surface area. This simple relationship, also 
known as geometric similarity, has important biological 
consequences. For example, as the size of an animal 
increases, it cannot remain isometric, otherwise its skeleton 
would not be able to tolerate its weight. The result is that its 
shape changes. Simply put, if a whippet were to increase 
to the size of an elephant, structural considerations would 























TBW: total body weight
Figure 4: Calculated remifentanil total body clearances of 40 
year old, 1.7 m tall males, using the “Minto” pharmacokinetic 
parameter set in which the “James” and “Janmahasatian” 
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LBM: Lean body mass
Figure 2: Anomalies resulting from calculations of lean body mass 
(LBM) for males of various heights using the “James” equation.  
At body mass indices of about 40 kg/m2, LBM values begin to 
decrease.
BMI: body mass index, BW: body weight, Eq: equation, FFM: fat-free mass,  
LBM: lean body mass
Figure 5: Estimation of LBM of the obese  
(Janmahasatian et al. Clin Pharmacokinet 2005; 44:1051-1065)
Estimation of LBM of the obese
Janmahasatian et al. 
Clin Pharmacokinet 2005; 44:1051-1065
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Estimation of LBM of the obese
Janmahasatian et al. 
Clin Pharmacokinet 2005; 44:1051-1065
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Propofol maintenance infusion rate (mg/min)
James LBM
Janmahasatian LBM
Male, age 40y, height 170 cm
Target (plasma) 4 µg/ml
“Schnider” model
LBM: lean body mass, TBW: total body weight
Figure 3: Maintenance propofol infusion rates to 40 year old,  
1.7 m tall males, using the “Schnider” pharmacokinetic parameter 
set in which the “James” and “Janmahasatian” equations are 
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The general allometric relationship is given by the 
exponential equation:
y=b.xa
Where “y” is the biological descriptor to be predicted, “x” 
the body weight, “b” a constant, and the exponent “a” 
the allometric coefficient. An allometric coefficient of 0.75 
has been found to apply empirically to many descriptors 
in physiology, pharmacology and morphology. Examples 
include oxygen consumption rate, glucose metabolism, 
cardiac output, drug clearance and respiratory minute 
volume.10 The clearance of drugs with high extraction 
ratios (a metabolic process) in human pharmacology can 
be scaled to a standard body weight, using an allometric 
coefficient of 0.75, according to the relationship:
CLi=CLstd.(BWi )
0.75
            BWstd
Where “CLstd” is the clearance of a standard individual 
of body weight (BWstd) (often 70 kg), and “CLi” is the 
clearance of the individual of body weight (“BWi”). Many 
estimates of the allometric exponent for drug clearance 
only approximate the value of 0.75. However, it appears 
that there is insufficient evidence to indicate that these are 
significantly different from 0.75.10 Physiological volumes, 
e.g. blood volume, cardiac stroke volume, tidal volume, vital 
capacity and skeletal muscle mass, are generally directly 
proportional to body weight, i.e. the allometric coefficient is 




          BWstd
 “Vi” and “Vstd” are the volumes of the individuals of body 
weights “BWi” and “BWstd”, respectively.  This proportional 
relationship has also been shown to apply to PK volumes 
of distribution, including the volume of distribution of the 
central compartment, the volume of distribution at steady 
state and the volume of distribution by area.11 The power 
law for interspecies scaling became widely accepted after 
he publications by Kleiber in 194712 and Brody in 1945,13 
suggesting that the basal metabolic rate could be scaled 
between species by using a simple allometric equation with 
a universal exponent of approximately 0.75. Theoretical and 
mathematical justification was published independently by 
West et al,14,15 Banavar et al16 and McMahon.17 However, 
there has been criticism and debate18 concerning the 
existence of a universal exponent for basal metabolic rate 
and extrapolation from the basal metabolic rate to PK. 
Many critics argue that the use of fixed exponents is not 
supported by empirical data.19 
With regard to allometric scaling of propofol dosing, two 
recent studies are intriguing. Knibbe et al20 determined 
and compared the PK parameters of rats, children and 
adults, and demonstrated that the clearances (total body 
clearance, as well as intercompartmental clearances) and 
the volumes of distribution could be scaled allometrically, 
with exponents approximating 0.75 for the clearances and 
unity for the volumes of distribution.  On scaling rat PK 
parameters to humans, they could also predict propofol 
concentrations in patients receiving propofol for sedation in 
the intensive care unit with satisfactory accuracy (r2 = 0.83).
Cortinez et al published a landmark study with regard to 
obesity and propofol.21 They studied 19 morbidly obese 
patients, and in addition, included data from a previous 
PK study on eight morbidly obese patients,22 as well 
as the original “Schnider” model study.7 They derived a 
three-compartment mammillary model in which total body 
clearance, as well as the intercompartmental clearances, 
were scaled allometrically according to a standard body 
weight of 70 kg with an exponent of 0.75. Similarly, the 
apparent volumes of distribution were also scaled to a 
standard body weight of 70 kg, but with an exponent of 
unity. It is interesting to note that a graph of clearance 
calculated according to the PK parameters of Knibbe et al 
and Cortinez et al form a continuum (Figure 7).
TCI: target-controlled infusion
Figure 6: Improved predictive performance of the “Minto” 
pharmacokinetic parameter set for remifentanil using the 
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Remifentanil and propofol are examples of lipid-soluble 
drugs that are excreted rapidly. Consequently, these 
considerations may apply to drugs with similar physi-
cochemical and pharmacological properties. It appears that 
dose-scaling methods for morbidly obese patients, either 
according to LBM or allometrically, have merit. It cannot 
be said which should be preferred at this stage. Whereas 
LBM is usually limited to adults, allometric scaling has the 
potential advantage of including children, obese children, 
normal adults and obese adults. Figure 8 depicts a graph 
of drug dosage for 1.75 m-tall males with BMI on the 
abscissa, and the dosage on the ordinate expressed as a 
percentage of the dose of a person of ideal body weight. 
Figure 8 illustrates that a morbidly obese person (BMI 
45 kg/m2) would receive 200% of the dose for a person of 
ideal body weight if the dosage was scaled according to 
TBW. On the other hand, allometric scaling would result in 
a 170% increase and scaling according to LBM/FFM, in a 
140% increase. Whether either method will prove to be of 
greater clinical significance remains to be seen because 
other factors must be considered in the morbidly obese, 
and most importantly the co-morbidities that are associated 
with the condition.
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IBW: ideal body weight, FFM: fat-free mass, TBW: total body weight. 
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Figure 7: Propofol: allometrically scaled clearance
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